The purpose of this study is to test the effects of lemborexant when used in combination with opioids (including buprenorphine). We are also interested in learning lemborexant might help improve sleep problems and problems related to opioid use (e.g., cravings, withdrawal), in people with opioid use disorder. Study participants will be randomly assigned in a two to one ratio to receive either lemborexant or placebo. Lemborexant (DAYVIGO®) is approved by the U. S. Food and Drug Administration (FDA) for treatment of insomnia.~In this study, Participants will be asked to do the following things:~Visit the CARI clinic and/or Motivate clinic at Jackson Center to complete study screening.~Visit the VCUHS Clinical Research Unit to complete an outpatient blood draw/testing visit.~Take either lemborexant or the placebo, depending upon which group subjects are assigned to.~Complete two (2) overnight study visits at the VCUHS Clinical Research Unit.~Complete 8 outpatient follow-up visits (broken into 2 four day visit groupings)~Have an EKG during screening and at each study visit (outpatient and inpatient)~Have an IV inserted into your arm for blood draws at the outpatient blood draw visit and each inpatient visit.~Record sleep in a sleep diary.~Take surveys and answer questions about health, mental health, medications used, drug use, and cravings.~Complete tasks on the computer.~Complete physical exams during screening, outpatient and inpatient visits.~Give permission for the researchers to collect information about opioid treatment, medical status, and other information from your medical record.~Participation in this study will last approximately 4 weeks. Approximately 18 people will participate in the drug interaction phase of this study.
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.